Medical Xpress

MARCH 8, 2023

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody. Their results are published in the Proceedings of the National Academy of Sciences.

Antibody 75

Antibody Gene Expression Gene Trials 75

Drug Discovery World

MARCH 21, 2023

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. So, what are the recent developments and how is the drug discovery sector tackling this common cancer? Improved diagnostics Diagnostics and screening are essential to the early treatment of colorectal cancer.

Drugs 52

Drugs Gene Expression RNA Clinical Trials 52

Drug Discovery World

MARCH 3, 2023

As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day , DDW has also reported on a number of developments in cancer drug discovery this week. The study authors hope that the discovery will pave the way for a clinical trial to see how effective the treatment is for women with the disease.

Drugs 52

Drugs Gene Expression Genome Genomics 52

Pharmaceutical Technology

JANUARY 24, 2023

The US Food and Drug Administration (FDA) has granted clearance for Neurogene’s investigational new drug (IND) application for NGN-401 to treat Rett syndrome. Neurogene stated that the FDA IND clearance allows it to commence a Phase II/II trial of NGN-401 in female paediatric Rett syndrome patients.

Gene Therapy 208

Gene Therapy Gene Gene Expression Regulation 208

Drug Discovery World

AUGUST 1, 2023

Synthetic biology is increasingly important to drug discovery and development. Towards the end of last year, Kite, a Gilead company, entered into an exclusive license agreement with synthetic biology company Refuge to access its gene expression platform to develop potential treatments for blood cancers.

Drugs 52

Drugs Gene Expression Engineer Gene 52

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells.

Trials 57

Trials Gene Silencing RNA Gene Expression 57

Drug Discovery World

AUGUST 22, 2023

The company has already completed three trials in patients, including a positive open label trial in metastatic breast cancer using a prototype capsule formulation. It delivers the drug at highly relevant blood levels within the timeframes expected of an enteric coated formulation.”

Gene Expression 52

Gene Expression In-Vitro Gene Trials 52

Drug Discovery World

MAY 16, 2023

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to SiSaf’s small interfering RNA (siRNA) therapeutic for skeletal disorder Autosomal Dominant Osteopetrosis Type 2 (ADO2). There are currently no approved treatments for Osteopetrosis ADO2 and no other treatments currently in clinical trials.

Gene Expression 52

Gene Expression RNA Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 13, 2023

Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. RNA transcript expression levels can provide insight into underlying biology – eg. DDW: Could you explain the process of transcriptomics? SB: Certainly.

RNA 52

RNA Drugs Gene Expression Gene 52

The Pharma Data

JULY 12, 2021

online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. the success rates in drug discovery?are

Drugs 52

Drugs Gene Expression Big Data Gene 52

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Drug Discovery World

OCTOBER 17, 2023

DDW Editor Reece Armstrong speaks to Benedikt Nilges , Head of Technology and Data Analytics at OMAPiX about spatial biology’s use in drug discovery and bettering our understanding of disease. This limits its efficacy in later stages of drug development or in the discovery and characterisation of biomarkers.

Gene Expression 52

Gene Expression Drugs Protein Gene 52

Drug Discovery World

DECEMBER 12, 2022

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month. . Everyone enjoys a good news story and the drug discovery and development sector is no exception. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 52

Drugs Gene Editing Genome Genomics 52

pharmaphorum

MARCH 10, 2021

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the case of AML that emerged in a trial of the drug in sickle cell disease. Shares in bluebird ticked up following the announcement.

Gene Therapy 52

Gene Therapy Gene Trials Gene Expression 52

Drug Discovery World

JANUARY 24, 2024

Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. Fibrocor is on track to complete all IND-enabling work to support IND filing and initiation of clinical trials in 2024. Only a few drugs have received approval for fibrotic diseases like IPF (idiopathic pulmonary fibrosis).

Research 59

Research Gene Expression Drugs Development 59

XTalks

JUNE 17, 2022

Eli Lilly’s Olumiant (baricitinib) has won US Food and Drug Administration (FDA) approval as the first systemic treatment for severe alopecia areata (AA), an autoimmune disorder that leads to patchy baldness. The drug was evaluated in 1,200 adult patients with severe AA.

FDA Approval 97

FDA Approval Gene Expression Cosmetics Trials 97

Delveinsight

JULY 24, 2021

Ovid Therapeutics is running Phase III clinical trials for its drug, Gaboxadol ( OV101 ). The drug is a small molecule, which selectively activates GABAA receptors located on the surface of nerve cells and away from the synapse. OV101 is considered as the first compound that targets disrupted tonic inhibition.

Gene Therapy 96

Gene Therapy Gene Expression Gene RNA 96

Camargo

JULY 8, 2021

At Camargo, we have worked with hundreds of investigators who have found new targets for established drugs. It is exciting to find new uses of drugs with known safety because these drugs can reach new groups of patients in a relatively short timeframe.

Development 130

Development Bioequivalency Gene Expression Drugs 130

XTalks

MAY 31, 2022

The spotlight for plaque psoriasis treatment is now on Vtama (tapinarof) cream (one percent), Dermavant’s discovery that has become the first steroid-free topical medication in its class approved by the US Food and Drug Administration (FDA). XTALKS WEBINAR: All Means All: The Road to Inclusivity in Clinical Trials.

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

Drug Discovery World

AUGUST 16, 2023

.” The findings suggest it might be possible to predict who will benefit from carboplatin and docetaxel using a range of different biomarkers and suggest further investigation of these biomarkers in clinical trials is warranted.

Genetics 52

Genetics Gene Hormones RNA 52

Drug Discovery World

JULY 10, 2023

If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World , it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. This was done to assess the accuracy of the team’s machine-learning algorithms.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. As such, teams are now researching a variety of medical applications for mRNA-based drugs. At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed.

RNA 52

RNA Protein Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 10, 2023

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Magnus Persson is a physician and scientist with a background in both academia and industry, working for the likes of Sanofi on clinical trials activities and across venture capital firms in the US.

Life Science 52

Life Science Drugs Gene Therapy Manufacturing 52

pharmaphorum

NOVEMBER 22, 2022

Cambridge, Massachusetts-based FogPharma has closed another impressive fundraising round, adding $178 million to the pot as it ushers its polypeptide-based drug candidates towards the clinic. Ut comes just as FogPharma is preparing to start clinical trials of alpha-helical polypeptide candidate FOG-001.

Gene Expression 52

Gene Expression Packaging Packaging Clinical Trials 52

Roots Analysis

AUGUST 31, 2023

The two types of gene regulation have been discussed below: Positive Gene Regulation: Activator is a protein molecule that helps to initiate a positive gene regulation. When activator binds to the operon, it either speeds up or permits gene expression.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Roots Analysis

NOVEMBER 3, 2023

NAMPT inhibitors are a class of drugs that target the enzyme nicotinamide phosphoribosyltransferase (NAMPT). NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. Several trials focused on evaluation of such drugs were discontinued in the past.

Development 40

Development Drugs Trials FDA Approval 40

Delveinsight

JANUARY 18, 2021

The company was running Phase III trials of the therapy for AS; however, the therapy flunked in the trial failing to meet its primary endpoint. For instance, GTX-102 , an antisense therapy silencing the gene expression by binding to the RNA molecule behind the regulation of its expression, has also secured USFDA Fast Track Designation.

Marketing 52

Marketing Gene Drugs Protein 52

XTalks

MARCH 13, 2024

Therapeutic Developments Related to Glaucoma The introduction of new classes of glaucoma medications, such as prostaglandin analogs, nitric oxide-donating drugs and Rho kinase inhibitors, has added to the pharmacological options available for managing IOP.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

Drug Discovery World

APRIL 16, 2023

The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting 2023, held April 14-19. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccination 52

Vaccination Vaccine Immune Response Gene Expression 52

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. Drugs, Testing and Vaccines. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Drug Discovery World

OCTOBER 3, 2022

The researchers performed flow-cytometry EMT characterisation of CTCs as compared to EMT gene expression in tumour tissue and investigated expression correlation with respect to clinical outcomes. The expression of EpCAM and N-cadherin were utilised to characterise CTC status as epithelial or EMT.

Gene Expression 52

Gene Expression Genome Genomics Clinical Trials 52

The Pharma Data

MARCH 3, 2022

Use of the drug verapamil to treat Type 1 diabetes continues to show benefits lasting at least two years, researchers report in the journal Nature Communications. The suggestion that verapamil might serve as a potential Type 1 diabetes drug was the serendipitous discovery of study leader Anath Shalev, M.D.,

Insulin 52

Insulin Gene Expression Gene Protein 52

Drug Discovery World

FEBRUARY 6, 2023

A key breakthrough area where big data analytics has shown tremendous scope and application is in systems biology, which has bolstered holistic drug research and development, ultimately to provide patients with access to the right therapies. It also helps to quickly address unplanned changes.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

The Pharma Data

DECEMBER 27, 2020

Even with the holidays among us, there were a number of clinical trial announcements. Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Here’s a look. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

Trial Also Met the Primary Endpoint in Patients With Low Levels of Eosinophils. In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, the trial met the primary endpoint with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

JANUARY 17, 2021

a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2a clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. GAITHERSBURG, Md.

Gene Expression 52

Gene Expression Trials Production Development 52

Drug Discovery World

JANUARY 23, 2023

Adult fibroblasts were cultured in a cocktail of transcription factors to reactivate embryonic gene expression patterns 2. The first in-person iPSC-derived regenerative therapy trial took place at Kyoto University, Japan. These cells present a highly scalable platform, capable of manufacturing advanced cellular therapeutics.

Gene Editing 52

Gene Editing Gene Engineer DNA 52